These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32821373)

  • 1. Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).
    Sun J; Gastman BR; McCahon L; Buchbinder EI; Puzanov I; Nanni M; Lewis JM; Carvajal RD; Singh-Kandah S; Desai AM; Raskin L; Nielson CM; Ismail R; Zager JS
    Melanoma Manag; 2020 Jun; 7(2):MMT41. PubMed ID: 32821373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).
    Perez MC; Zager JS; Amatruda T; Conry R; Ariyan C; Desai A; Kirkwood JM; Treichel S; Cohan D; Raskin L
    Melanoma Manag; 2019 Jul; 6(2):MMT19. PubMed ID: 31406563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries.
    van Akkooi ACJ; Haferkamp S; Papa S; Franke V; Pinter A; Weishaupt C; Huber MA; Loquai C; Richtig E; Gokani P; Öhrling K; Louie KS; Mohr P
    Adv Ther; 2021 Feb; 38(2):1245-1262. PubMed ID: 33368016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.
    Fröhlich A; Hoffmann F; Niebel D; Egger E; Kukuk GM; Toma M; Sirokay J; Bieber T; Landsberg J
    Front Oncol; 2020; 10():611. PubMed ID: 32457834
    [No Abstract]   [Full Text] [Related]  

  • 5. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
    Corrigan PA; Beaulieu C; Patel RB; Lowe DK
    Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Talimogene laherparepvec: overview, combination therapy and current practices.
    O'Donoghue C; Doepker MP; Zager JS
    Melanoma Manag; 2016 Dec; 3(4):267-272. PubMed ID: 30190898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of talimogene laherparepvec for the treatment of melanoma.
    Broman KK; Zager JS
    Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma.
    Burke EE; Zager JS
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):469-473. PubMed ID: 29557682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
    Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
    Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study.
    Kleemann J; Jäger M; Valesky E; Kippenberger S; Kaufmann R; Meissner M
    Cancer Manag Res; 2021; 13():5699-5709. PubMed ID: 34290528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of talimogene laherparepvec: A first-in-class oncolytic viral treatment of advanced melanoma.
    Haitz K; Khosravi H; Lin JY; Menge T; Nambudiri VE
    J Am Acad Dermatol; 2020 Jul; 83(1):189-196. PubMed ID: 32004650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
    Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG
    BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
    Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
    EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience.
    Carr MJ; Sun J; DePalo D; Rothermel LD; Song Y; Straker RJ; Baecher K; Louie RJ; Stahlie EHA; Wright GP; Naqvi SMH; Kim Y; Sarnaik AA; Karakousis GC; Lowe MC; Delman KA; van Akkooi ACJ; Ollila DW; Collichio F; Zager JS
    Ann Surg Oncol; 2022 Feb; 29(2):791-801. PubMed ID: 34648098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series.
    Sun L; Funchain P; Song JM; Rayman P; Tannenbaum C; Ko J; Mcnamara M; Marcela Diaz-Montero C; Gastman B
    J Immunother Cancer; 2018 May; 6(1):36. PubMed ID: 29764498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study.
    Ghebrehiwet M; Pavlis J; Gomez-Meade C
    Cureus; 2024 Sep; 16(9):e69605. PubMed ID: 39429342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database.
    Louie KS; Banks V; Scholz F; Richter H; Öhrling K; Mohr P; Haferkamp S
    Future Oncol; 2020 Mar; 16(8):317-328. PubMed ID: 32050787
    [No Abstract]   [Full Text] [Related]  

  • 20. Retreatment with talimogene laherparepvec for advanced melanoma.
    Hu J; Masoud SJ; Ravichandran S; Beasley GM; Mosca PJ
    Immunotherapy; 2020 Nov; 12(16):1167-1172. PubMed ID: 32840157
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.